We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Minimally Invasive Prostate Biopsy Procedure Improves Cancer Detection

By MedImaging International staff writers
Posted on 11 May 2023
Image: A new transperineal prostate biopsy procedure with fusion guided technology can detect prostate cancer (Photo courtesy of Freepik)
Image: A new transperineal prostate biopsy procedure with fusion guided technology can detect prostate cancer (Photo courtesy of Freepik)

Prostate biopsy is a commonly performed invasive diagnostic procedure. With the annual global incidence of new prostate cancers standing at 1.4 million, over 3 million prostate biopsies are performed each year. Traditionally, an elevated prostate-specific antigen blood test and/or a flagged digital rectal exam led to a transrectal biopsy in order to check for prostate cancer. But now, a novel transperineal prostate biopsy procedure, utilizing fusion-guided technology, is enhancing imaging precision and potentially boosting cancer detection in clinical settings.

The transperineal biopsy procedure, coupled with 3D MRI fusion-guided technology, allows physicians to obtain a more representative collection of tissue samples with a reduced post-procedure infection rate, all while bypassing the rectum. Unlike the traditional transrectal biopsy where the biopsy needle is passed through the rectal lining to access the prostate, the transperineal biopsy procedure avoids the rectum, with the biopsy needle passing through the perineum, the area of skin located between the base of the scrotum and the rectum. This is significant because the transrectal approach heightens the risk of transferring fecal matter and bacteria into the prostate.

For patients undergoing transrectal biopsies, antibiotics are prescribed to mitigate the roughly 1 to 2% risk of infection. However, for transperineal biopsies, antibiotics are usually unnecessary or administered in lower doses due to the infection rate being nearly zero. Furthermore, the 3D MRI fusion guided technology enhances the precision in identifying potential cancer within the prostate. Doctors can integrate the MRI findings with ultrasound imaging to generate a three-dimensional view of the prostate. This increased accuracy in imaging enables physicians to ensure they are targeting any suspicious areas, including those that are hard to access through transrectal methods.

Ultrasound Needle Guidance System
SonoSite L25
X-ray Diagnostic System
FDX Visionary-A
Mobile X-Ray System
K4W
Breast Localization System
MAMMOREP LOOP

Channels

Industry News

view channel
Image: MIM KineticID is 510(k)-pending software for dynamic PET imaging and kinetic modeling, enabling time-based radiotracer analysis for clinical and research decisions (Photo courtesy of GE Healthcare)

GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026

Nuclear medicine is expanding rapidly as health systems adopt theranostics and broaden access to radiopharmaceuticals, increasing demand for scalable operations and consistent diagnostic confidence.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.